Therefore, the pharmacological activation of the Keap1/Nrf2 system is expected to enhance astrocytic protective mechanisms against ROSs, leading to a novel therapeutic strategy for the treatment of Parkinson disease. The gene discussed is KEAP1; the disease is Parkinson disease.